Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week). No patient achieved a partial response. The dose-limiting toxic effect was granulocytopenia. Mitoxantrone is ineffective in malignant melanoma.
